Article
Optimal aNtiplatelet pharmacotherapy guided by bedSIDE genetic or functional TESTing in elective PCI patients: A pilot study: ONSIDE TEST pilot.
Cardiology journal - 1 Jan 2017
Koltowski Lukasz, Tomaniak Mariusz, Aradi Daniel, Huczek Zenon, Filipiak Krzysztof J, Kochman Janusz, Balsam Pawel, Gajda Sylwia, Opolski Grzegorz
Abstract excerpt
BACKGROUND: Dual antiplatelet therapy (DAPT) is recommended after elective percutaneous coronary intervention (PCI) in stable coronary artery disease (SCAD) patients; however, still one-third of patients do not obtain adequate platelet inhibition that may result in increased cardiovascular risk. The aim of the ONSIDE TEST study is to evaluate the clinical impact of point-of-care genotyping- and platelet...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
